2011
DOI: 10.1016/j.rdc.2011.01.009
|View full text |Cite
|
Sign up to set email alerts
|

Molecular Diagnosis of Myopathies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 86 publications
0
1
0
Order By: Relevance
“…An example of this was demonstrated by a population-based study which reported that the highest epilepsy diagnostic yield was obtained via MRI (65%), and, although WES/WGS was performed in only 26/116 cases (22%), the associated diagnostic yield reached 58% [74]. Additionally, the diagnosis of certain conditions associated with neuromyopathy, such as MD, and CMS can avoid the need for muscle biopsy by instead performing genetic testing [131]. Moreover, NGS may become a tool for early intervention or trial treatment, thereby greatly reversing disease trajectory [132,133].…”
Section: Concluding Remarks and Future Perspectivesmentioning
confidence: 99%
“…An example of this was demonstrated by a population-based study which reported that the highest epilepsy diagnostic yield was obtained via MRI (65%), and, although WES/WGS was performed in only 26/116 cases (22%), the associated diagnostic yield reached 58% [74]. Additionally, the diagnosis of certain conditions associated with neuromyopathy, such as MD, and CMS can avoid the need for muscle biopsy by instead performing genetic testing [131]. Moreover, NGS may become a tool for early intervention or trial treatment, thereby greatly reversing disease trajectory [132,133].…”
Section: Concluding Remarks and Future Perspectivesmentioning
confidence: 99%